![Jeremy David Lack](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeremy David Lack
Direktor/Vorstandsmitglied bei
Alcresta Therapeutics, Inc.
Profil
Dr. Jeremy D.
Lack is a Partner at RA Capital Management LP.
He is on the Board of Directors at Alcresta Therapeutics, Inc. His primary responsibility is to build out credit and structured capital solutions across the RA Capital platform with a focus on commercial stage healthcare and life sciences companies.
Previously, he was a Partner and President at Athyrium Capital Management, a Managing Director at the Cortec Group, and a Principal at New Leaf Venture Partners.
He also founded and led Durata Therapeutics (NASDAQ: DRTX; acquired by Actavis), a spin-out from Pfizer focused on antibiotics.
Earlier in his career, he was a consultant at McKinsey & Company and served as the Director of Strategic Planning for the New York City Department of Education.
He holds a BS with honors from the School of Industrial and Labor Relations at Cornell University and a DPhil in Biochemistry from the University of Oxford, where he was a Marshall Scholar.
Aktive Positionen von Jeremy David Lack
| Unternehmen | Position | Beginn |
|---|---|---|
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops enzyme-based products that deliver enzymatic solutions to those living with rare diseases | Direktor/Vorstandsmitglied | - |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Portfolio Manager-Fixed Income | 01.09.2024 |
Ehemalige bekannte Positionen von Jeremy David Lack
| Unternehmen | Position | Ende |
|---|---|---|
Cortec Group Management Services LLC
 Cortec Group Management Services LLC Investment ManagersFinance Cortec Group invests in middle market companies located in the United States and Canada with an EBITDA of USD 10 - 50 million and revenues of USD 40 - 300 million. The firm focuses on companies operating in the fields of healthcare products & services, consumer products, manufactured products, distribution & specialty products and services. It participates in buyout transactions with an investment size of USD 100 - 500 million and acquires controlling interests. | Corporate Officer/Principal | 31.12.2012 |
| DURATA THERAPEUTICS INC | Gründer | - |
Athyrium Capital Management LP
 Athyrium Capital Management LP Investment ManagersFinance Athyrium specializes in the healthcare sector and is primarily focused on longer-term investments including private equity, public equity and structured investments. Structured investments are investments composed of one or more of the following instruments: convertibles, loans, bonds, preferred stock, common stock, warrants, and royalties. The firm most typically employs a fundamental buy and hold strategy. Their approach to analysis is typically private equity-like in nature and includes sourcing, due diligence, structuring and negotiating transactions, and actively monitoring portfolio investments. | Präsident | - |
The New York City Department of Education
 The New York City Department of Education General GovernmentGovernment Operates the public schools | Corporate Officer/Principal | - |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Berater | - |
Ausbildung von Jeremy David Lack
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
36
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cortec Group Management Services LLC
Cortec Group Management Services LLC Investment ManagersFinance Cortec Group invests in middle market companies located in the United States and Canada with an EBITDA of USD 10 - 50 million and revenues of USD 40 - 300 million. The firm focuses on companies operating in the fields of healthcare products & services, consumer products, manufactured products, distribution & specialty products and services. It participates in buyout transactions with an investment size of USD 100 - 500 million and acquires controlling interests. | Finance |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Leaf Venture Partners LLC
 New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Ventures invests in public and private healthcare technology companies located in the US. The firm participates in early and later-stage capital requirements. | Finance |
The New York City Department of Education
The New York City Department of Education General GovernmentGovernment Operates the public schools | Government |
Durata Therapeutics, Inc.
 Durata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics for infectious diseases and acute illnesses | Health Technology |
Athyrium Capital Management LP
Athyrium Capital Management LP Investment ManagersFinance Athyrium specializes in the healthcare sector and is primarily focused on longer-term investments including private equity, public equity and structured investments. Structured investments are investments composed of one or more of the following instruments: convertibles, loans, bonds, preferred stock, common stock, warrants, and royalties. The firm most typically employs a fundamental buy and hold strategy. Their approach to analysis is typically private equity-like in nature and includes sourcing, due diligence, structuring and negotiating transactions, and actively monitoring portfolio investments. | Finance |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops enzyme-based products that deliver enzymatic solutions to those living with rare diseases | Health Technology |
